12th Annual CMHC

October 4-7

Boston, MA

2017 Professional Medical Education

Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies. There are no additional fees to attend once you have registered for the 12th Annual Congress and meals or refreshments may be provided. Register for the 12th Annual CMHC today and attend these activities.


Non-CME Symposium · Wednesday, October 4, 2017 · 11:00am – 12:00pm

The Cardiometabolic Implications of Obesity and Nutritional Strategies for Prevention

Faculty: Frank B. Hu, MD, PhD

The prevalence of obesity in the US has reached epidemic proportions. Obesity is defined as having a body mass index (BMI) greater than 30; rates for it have more than doubled in adults and children since 1970. Recent figures indicate over 78 million US adults are obese today. Obesity is associated with numerous health issues including arthritis, cancer and cardiovascular disease (CVD). Obesity is linked to multiple comorbid conditions underlying CVD including hypertension, diabetes, and dyslipidemia and is often due to consequences of heart-damaging lifestyle choices including lack of exercise and poor dietary choices. Diet is critical to development and prevention of heart disease and is a key modifiable risk factor. In this presentation, Dr. Hu will review various studies highlighting implications of obesity on conditions associated with –and contributing to—CVD. He will discuss research on dietary changes to reduce cardiometabolic risk and improve outcomes in this patient population.

Sponsored by Metagenics Institute


Non-CME Lunch Symposium · Wednesday, October 4, 2017 · 12:00pm – 1:15pm

Repatha® (evolocumab): Take the Next Step

Faculty: Yehuda Handelsman, MD

This program provides an overview of Repatha®, including dosing and administration. A discussion of appropriate patients will be supplemented by relevant hypothetical examples.

Sponsored by Amgen Inc.


Non-CME Symposium (Light Bites) · Wednesday, October 4, 2017 · 5:00pm – 6:00pm

Awaken a Transformation in Type 2 Diabetes Management

Faculty: Yehuda Handelsman, MD

Sponsored by Janssen Pharmaceuticals, Inc.


Non-CME Symposium (Light Bites) · Wednesday, October 4, 2017 · 6:00pm – 7:00pm

Advancements in the Management of Patients With Type 2 Diabetes: Results From a Large Cardiovascular Outcomes Trial

Faculty: Michael H. Davidson, MD

This program will review data on advancements in Type 2 Diabetes management from a large cardiovascular outcomes trial.

Sponsored by Novo Nordisk


Non-CME Dinner Symposium · Wednesday, October 4, 2017 · 7:00pm – 8:00pm

JARDIANCE® (empagliflozin) Tablets: Evolving Clinical Development

Faculty: Rajat Deo, MD

This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will also have the opportunity to ask the faculty questions about the data presented.

Sponsored by Boehringer-Ingelheim Pharmaceuticals, Inc./Lilly USA


Non-CME Dinner Symposium · Thursday, October 5, 2017 · 6:00pm – 7:00pm

Clinical Evaluation of Pure EPA

Faculty: Matthew J. Budoff, MD

Hear an expert medical presentation entitled Clinical Evaluation of Pure EPA, which provides a brief overview of TGs and research on other lipids, lipoproteins and inflammatory parameters related to CV disease, despite statin-controlled LDL-C. The clinical program for pure EPA VASCEPA® (icosapent ethyl), including the ongoing CV outcome trial REDUCE-IT™, will be reviewed. In the treatment of patients with elevated TGs, the clinical difference between and effects of EPA and DHA omega-3s and the issues concerning patient use of fish oil supplements will be discussed.

Sponsored by Amarin Pharma, Inc.


Non-CME Dinner Symposium · Friday, October 6, 2017 · 7:00pm – 8:15pm

Hypertriglyceridemia & Pancreatitis: Separating Secondary Causes from Familial Chylomicronemia Syndrome (FCS)

Faculty: Paul D. Rosenblit, MD, PHD, FACE, FNLA

This program provides clinicians with information on Familial Chylomicronemia Syndrome (FCS), a disease in which inherited defects result in the accumulation of chylomicrons in the plasma causing acute pancreatitis and sequelae which can impact daily life including recurrent pain, recurrent acute pancreatitis, and permanent pancreatic damage.

Objectives for attending clinicians include:

  • Differentiate the FCS patient from patients with secondary causes of hypertriglyceridemia
  • Appreciate the importance of FCS diagnosis
  • Understand the value of connecting FCS patients to educational resources and the FCS patient community

Sponsored by Akcea Therapeutics